2 learning resources available for this topic
Neonatal screening involves systematic testing of newborns within the first few days of life to identify serious genetic, metabolic, and endocrine disorders before symptoms develop. Early detection through these standardized blood tests enables prompt treatment that can prevent intellectual disability, organ damage, and death in affected infants.
Many screened conditions involve enzyme deficiencies or hormonal imbalances that disrupt normal metabolic pathways, leading to toxic accumulation of substrates or deficiency of essential products. Without early intervention, these biochemical abnormalities can cause irreversible damage to developing organs, particularly the brain, liver, and endocrine systems.
The timing of neonatal screening is critical, typically performed between 24-72 hours after birth when metabolic processes have stabilized but before clinical symptoms manifest. Healthcare providers must understand that normal screening results don't exclude all genetic conditions, while abnormal results require immediate follow-up testing and specialist referral to confirm diagnosis and initiate treatment protocols.